Heart Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
Historical control group (looking back at past patients):
- Adults aged 18 or older
- People who have had a specific type of heart bypass surgery (called MIDCAB) using an internal chest artery to bypass a blocked heart artery
Prospective group (new participants going forward):
- Adults aged 18 or older
- People who have had a specific type of heart bypass surgery (called MIDCAB) using an internal chest artery to bypass a blocked heart artery
- People who have signed a consent form agreeing to take part in the trial
Who may not be able to join:
Historical control group:
- People who received certain clot-dissolving or blood-thinning medications (fibrinolytics or GP IIb/IIIa inhibitors)
- People who have previously had bleeding inside the brain
- People with a known condition that causes abnormal bleeding
- People who had both a MIDCAB procedure and a catheter-based heart procedure (PCI) performed at the same time
- People with serious kidney or liver disease
- People who are pregnant or breastfeeding
Prospective group:
- People who are unconscious
- People with a known allergy or sensitivity to the study drug (cangrelor)
- People who recently received certain clot-dissolving or blood-thinning medications (fibrinolytics or GP IIb/IIIa inhibitors)
- People who have previously had bleeding inside the brain
- People with a known condition that causes abnormal bleeding
- People who had both a MIDCAB procedure and a catheter-based heart procedure (PCI) performed at the same time
- People with serious kidney or liver disease
- People who are pregnant or breastfeeding
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Marco Valgimigli, Prof. Dr. Med., Cardiocentro Ticino
Phone: +41 91 811 51 11
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Excessive CABG-related bleeding during and after MIDCAB surgery
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.